NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Accuray Incorporated (ARAY) Stock Analysis

Accuray Incorporated (ARAY) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

ARAY

$0.27

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARAY with… →

ARAY Key Statistics

As of Sep 4, 2026
Trading
Open
$0.27
Previous Close
$0.27
Day's Range
0.25–0.27
52-Week Range
0.22–2.10
Volume
280.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.39
Valuation
Market Cap
$31.87M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
29.49
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.08
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.40
Financials (FY)
Revenue (FY)
$458.51M+2.68%
Net Income (FY)
−$1.59M
Profit marginThe share of revenue left as profit after all costs and taxes.
−12.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
119.44M
1-Year Return
−82.12%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.41M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARAY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−67.07%
2025−58.59%
2024−30.04%
2023+35.41%
2022−56.18%
2021+14.39%
2020+47.87%
2019−17.30%
2018−20.70%
2017−6.52%
2016 (partial year)−15.60%

As of September 4, 2026.

ARAY Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$458.51M−$1.59M−0.3%
2024$446.55M−$15.55M−3.5%
2023$447.61M−$9.28M−2.1%
2022$429.91M−$5.35M−1.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$458.51M$146.97M$7.84M−$1.59M−0.3%
2024$446.55M$142.92M$504.00K−$15.55M−3.5%
2023$447.61M$153.96M$2.38M−$9.28M−2.1%
2022$429.91M$159.96M$8.15M−$5.35M−1.2%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

ARAY Valuation vs Medical Devices Median

Median of 151 stocks
MetricARAYMedical Devices medianvs median
P/S ratio0.082.980.0x the median
Profit margin−12.24%−1.69%10.5 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Accuray Incorporated (ARAY) at $31.87M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 809.

The 52-week range on file runs from $0.22 to $2.10. ARAY last closed at $0.27 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 22.73% above that 52-week low.

Financial Health

In fiscal 2025, Accuray Incorporated reported revenue of $458.51M. That is +2.68% against the prior fiscal year, when revenue was $446.55M. The same year closed with a net loss of $1.59M. Profit margin runs at −12.24%. That is 10.5 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.4.

Across the 4 fiscal years on file, revenue moves from $429.91M in 2022 to $458.51M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 29.49. The price-to-sales ratio is 0.08. On price-to-sales that is 0 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −82.12%. Across 10 years the annualized return works out at −25.91%. Beta against the wider market is reported at 1.39. Daily returns over the trailing 10 years annualize to a volatility of 68.46%.

Growth & Income

No dividend is on file for ARAY.

The strongest complete calendar year on file is 2020 at +47.87%; the weakest is 2025 at −58.59%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is −67.07%.

Peer Comparison

Accuray Incorporated (ARAY) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Accuray Incorporated ARAY $31.87M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Accuray Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Accuray Incorporated

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Visit website →